Bayer Aktienges ADR (BAYRY)

$BAYRY confusing move today on the recent FDA approval. Would've liked to see this move into the 8.30s instead

$SLS Undervalued, buying more at this easy $15. To $25. Before the buyout. $MRK $BAYRY $JNJ #Sellas_life. $SLS #NEWS trial met all endpoints, demonstrating strong efficacy and favorable safety and tolerability with robust anti-tumor activity. #StockMarket

$BAYRY just scored a key FDA win — here's why it matters 👀 The label expansion makes Kerendia the only approved non-steroidal MR antagonist for both chronic kidney disease in type 2 diabetes and heart failure. See what this means for BAYRY’s growth outlook 👉 https://www.zacks.com/stock/news/2579653/bayer-gets-fda-nod-for-label-expansion-of-kerendia-in-heart-failure?cid=sm-stocktwits-2-2579653-teaser-1491&ADID=SYND_STOCKTWITS_TWEET_2_2579653_TEASER_1491

$BAYRY: Bayer receives FDA approval for KERENDIA https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20250714050051BAYRY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

$BAYRY rallies 67% YTD — what's driving the surge? 🚀 Bayer's elinzanetant just bagged its first global approval in the UK for treating moderate to severe vasomotor symptoms associated with menopause, marking a compelling growth catalyst for their pharma division. This hormone-free therapy could redefine care for millions worldwide. Discover the full potential here 👉 https://www.zacks.com/stock/news/2573769/bayer-wins-hormone-free-treatment-approval-for-women-in-the-uk?cid=sm-stocktwits-2-2573769-body-1314&ADID=SYND_STOCKTWITS_TWEET_2_2573769_BODY_1314

First global green light for $BAYRY — and it’s a big one 👀 Lynkuet just got UK approval as the first hormone-free treatment for menopause-related hot flashes. See why this could be a game changer 👉 https://www.zacks.com/stock/news/2573769/bayer-wins-hormone-free-treatment-approval-for-women-in-the-uk?cid=sm-stocktwits-0-2573769-teaser-1313&ADID=SYND_STOCKTWITS_TWEET_0_2573769_TEASER_1313

$BAYRY just entered human trials for a breakthrough eye therapy 👁️🚀 Phase I/II study launched for OpCT-001, its experimental cell therapy targeting primary photoreceptor diseases. Early-stage, but potential game-changer — details here 👉 https://www.zacks.com/stock/news/2567477/bayer-begins-phase-iii-study-on-cell-therapy-for-eye-disease?cid=sm-stocktwits-2-2567477-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2567477_TEASER

$BAYRY surges 56.6% YTD — what’s fueling the rally? 🚀 👁️ BlueRock's OpCT-001 enters phase I/IIa study for retinal diseases 🧬 Expanded pipeline with cell & gene therapy innovations 🔋 Promising Parkinson's therapy, bemdaneprocel, with Fast Track designation Discover Bayer's strategic moves here 👉 https://www.zacks.com/stock/news/2567477/bayer-begins-phase-iii-study-on-cell-therapy-for-eye-disease?cid=sm-stocktwits-2-2567477-body-924&ADID=SYND_STOCKTWITS_TWEET_2_2567477_BODY_924

$BAYRY why red today? 🙄

$BAYRY trending up?

$BAYRY I think it’s time to cut my 20% losses and put this money in bitcoin or bbai.

$BAYRY nice recovery on yesterday's selloff

$BAYRY Supreme court has interest in taking Roundup case and is seeking Trump Administration for thoughts. Here's to hoping RFK doesn't wreck this. As the glyphosate study over the weekend helped nothing. https://www.reuters.com/legal/litigation/us-supreme-court-seeks-justice-department-views-bayers-roundup-appeal-2025-06-30/

$BBIO $BAYRY BridgeBio raises $300M via parital capped monetization of European royalty BridgeBio Pharma (BBIO)has sold a portion of royalties due to the Company from sales of BEYONTTRA in Europe to HealthCare Royalty and funds managed by Blue Owl Capital for $300M. This royalty financing agreement monetizes select anticipated royalties and provides immediate less-dilutive capital to the Company. Under the terms of the agreement, BridgeBio has received $300M from HCRx and Blue Owl managed funds in exchange for 60% of royalties on the first $500M of annual BEYONTTRA net sales in Europe. The agreement includes an initial cap of 1.45x. Once the applicable cap is met, no further payments will be owed to the investors. In March 2024, BridgeBio entered into an exclusive licensing agreement with Bayer Consumer Care (BAYRY) to commercialize BEYONTTRA in Europe for the treatment for ATTR-CM. To date, BridgeBio has received $210M in upfront and regulatory milestones, and anticipates receiving a further $75 million in near-term milestone payments, along with tiered royalties starting in the low-30% range on net sales of BEYONTTRA in Europe. Acoramidis is approved in the U.S. as Attruby by the FDA and in Europe as BEYONTTRA by the European Commission. It is also approved as BEYONTTRA by the Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency with all labels specifying near-complete stabilization of TTR.

$BAYRY https://link.springer.com/article/10.1186/s12940-025-01187-2

$BAYRY https://www.marketscreener.com/quote/stock/BAYER-AG-436063/news/Bayer-EU-approves-treatment-for-AMD-and-DMO-50351028/

$BAYRY 🔥📈 https://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-bayer-aktiengesellschaft-otcmktsbayry-to-buy-2025-06-26/

$BAYRY Targets 👇🏽📈 https://invezz.com/news/2025/06/26/bayer-share-price-is-rising-does-it-have-more-upside/

$BAYRY https://www.tsinghua.edu.cn/en/info/1245/4586.htm

$BAYRY https://www.fiercebiotech.com/biotech/exelixis-blockbuster-hopeful-beats-bayer-drug-pivotal-cancer-trial-sending-stock-25

$CPHI Featured Alongside Global Pharma Leaders: According to the official Jinan government website, CPHI’s bacterial infection treatment was listed under the city’s supervised drug pricing catalogue on June 3, 2025. This inclusion means the product is now available in Jinan’s regulated public healthcare system, a city with a population of over 9 million. In the same list, major global pharmaceutical companies are also featured: 1. $NVS (Novartis): Complex Substitution – likely a specialty cardiovascular or metabolic drug. 2. $BLCO (Bausch + Lomb): Runshu Eye Drops – used for eye dryness and irritation relief. 3. $BAYRY (Bayer): Glucobay (Acarbose) – an oral medication used to treat type 2 diabetes. 4. $SNY (Sanofi): Amlodipine (Amory) – a blood pressure and angina medication. ....and many more. All these drug companies are expanding presence within China’s public healthcare and pharmaceutical retail network.

$ORINY $BAYRY Orion says Bayer reports CHMP recommends third indication for darolutamide Orion's (ORINY) collaboration partner Bayer (BAYRY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor, plus androgen deprivation therapy for marketing authorisation in the European Union for the treatment of patients with metastatic hormone-sensitive prostate cancer. The CHMP recommendation is based on positive results from the pivotal Phase III ARANOTE trial which showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with mHSPC. A final decision on marketing authorisation from the European Commission is anticipated in the coming months. The U.S. Food and Drug Administration recently approved darolutamide in combination with ADT for mHSPC in June 2025, making it the first and only in the US and FDA-approved ARi for the treatment of patients with mHSPC, in combination with ADT, with or without chemotherapy. Darolutamide, under the brand name Nubeqa, is approved in over 85 countries for use with ADT and docetaxel in mHSPC, and with ADT alone in non-metastatic castration-resistant prostate cancer in patients who are at high risk of developing metastatic disease. Darolutamide is developed jointly by Orion and Bayer.